Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of ALI/ARDS patients with COVID-19
The administration of the neutrophil elastase inhibitor sivelestat may improve clinical outcomes in COVID-19 patients with ALI/ARDS. These findings suggest that sivelestat could be considered an effective treatment option to alleviate pulmonary inflammatory injury caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Authors
- Shuang Wei (ORCID: https://orcid.org/0000-0001-5322-9667)
- Mengyu Cheng
- Yuan Chen (ORCID: https://orcid.org/0000-0001-9059-3839)
- Jian Li (ORCID: https://orcid.org/0000-0002-9333-3255)
- Lei Wang (ORCID: https://orcid.org/0000-0001-5668-4737)
- Hu Liu (ORCID: https://orcid.org/0000-0003-3840-8135)
- Xueli Bai
- Junping Yin (ORCID: https://orcid.org/0000-0002-9270-2071)
- Ruiying Wang (ORCID: https://orcid.org/0000-0001-6224-8480)
- Xiansheng Liu (ORCID: https://orcid.org/0000-0002-9598-5054)
Institutions
- Shanxi Medical University (CN)
- Shanxi Academy of Medical Sciences (CN)
- Tongji Hospital (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Heliyon
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1016/j.heliyon.2024.e36337
- Citations
- 4
- Primary Topic
- Respiratory Support and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Guangzhou Medical University
- State Key Laboratory of Respiratory Disease
- Health Commission of Shanxi Province
- ShanXi Science and Technology Department